Becton Dickinson 관리

관리 기준 확인 1/4

Becton Dickinson CEO는 Tom Polen, Apr2017 에 임명되었습니다 의 임기는 5.42 년입니다. 총 연간 보상은 $ 14.19M, 8.6% 로 구성됩니다. 8.6% 급여 및 91.4% 보너스(회사 주식 및 옵션 포함). 는 CHF 6.63M 가치에 해당하는 회사 주식의 0.01% 직접 소유합니다. 6.63M. 경영진과 이사회의 평균 재임 기간은 각각 1.2 년과 5.8 년입니다.

주요 정보

Tom Polen

최고 경영자

US$14.2m

총 보상

CEO 급여 비율	8.6%
CEO 임기	5.4yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	5.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Tom Polen 의 보수는 Becton Dickinson 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$767m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b
Jun 30 2019	n/a	n/a	US$784m
Mar 31 2019	n/a	n/a	US$926m
Dec 31 2018	n/a	n/a	US$894m
Sep 30 2018	US$6m	US$850k	US$159m
Jun 30 2018	n/a	n/a	US$621m
Mar 31 2018	n/a	n/a	-US$99m
Dec 31 2017	n/a	n/a	US$294m
Sep 30 2017	US$4m	US$761k	US$1b
Jun 30 2017	n/a	n/a	US$759m
Mar 31 2017	n/a	n/a	US$1b
Dec 31 2016	n/a	n/a	US$1b
Sep 30 2016	US$3m	US$651k	US$976m

보상 대 시장: Tom 의 총 보상 ($USD 14.19M )은 Swiss 시장( $USD 4.48M ).

보상과 수익: Tom 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Tom Polen (49 yo)

5.4yrs

테뉴어

US$14,189,333

보상

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Co...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Polen	President	5.4yrs	US$14.19m	0.010% CHF 6.6m
Christopher DelOrefice	Executive VP & CFO	1yr	US$1.61m	데이터 없음
Samrat Khichi	Executive VP of Corporate Development	4.8yrs	US$3.53m	0.0021% CHF 1.4m
Thomas Spoerel	Senior VP	2.9yrs	데이터 없음	0.00054% CHF 353.3k
Elizabeth McCombs	Executive VP & Chief Technology Officer	1.4yrs	데이터 없음	데이터 없음
Joseph Smith	Senior VP	less than a year	데이터 없음	데이터 없음
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	less than a year	데이터 없음	데이터 없음
Francesca DeMartino	Senior VP & Head of Investor Relations	less than a year	데이터 없음	데이터 없음
Michelle Quinn	Senior VP and Chief Ethics & Compliance Officer	no data	데이터 없음	데이터 없음
Troy Kirkpatrick	Vice President of Public Relations	no data	데이터 없음	데이터 없음
Antoine Ezell	Executive VP	2.7yrs	데이터 없음	0.0026% CHF 1.7m
Ginny Blocki	Senior VP of Global Marketing & Product Management	less than a year	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 000912061 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Polen	President	2.7yrs	US$14.19m	0.010% CHF 6.6m
Joseph Smith	Senior VP	less than a year	데이터 없음	데이터 없음
John DeFord	Co-Chair of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Marshall Larsen	Independent Lead Director	15yrs	US$386.17k	0.0083% CHF 5.5m
Robert Eckert	Independent Director	6yrs	US$321.17k	0.0022% CHF 1.4m
Timothy Ring	Independent Director	5.7yrs	US$326.17k	0.028% CHF 18.4m
Jeffrey Henderson	Independent Director	4.1yrs	US$326.17k	0.0013% CHF 863.7k
Christopher Ian Jones	Independent Director	12.2yrs	US$351.17k	0.0066% CHF 4.3m
Bertram Scott	Independent Director	20yrs	US$346.17k	0.011% CHF 7.3m
Catherine Burzik	Independent Director	9.7yrs	US$351.17k	0.0044% CHF 2.9m
Claire Fraser-Liggett	Member of Scientific Advisory Board & Independent Director	15.8yrs	US$346.17k	0.0076% CHF 4.9m
Carrie Byington	Independent Director	less than a year	데이터 없음	0% CHF 0

5.8yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 000912061 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2022/09/24 05:37
장 마감 주가	2022/06/27 00:00
수익	2022/06/30
연간 수익	2021/09/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Becton, Dickinson and Company 40 애널리스트 중 14 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Adam Feinstein	Barclays

Becton Dickinson 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Becton, Dickinson and Company Appoints Pamela Spikner as Senior Vice President, Chief Accounting Officer and Controller, Effective January 20, 2025

Becton, Dickinson and Company, Annual General Meeting, Jan 28, 2025

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

Becton, Dickinson and Company Announces Executive Changes

Recent updates

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 31, 2025

Becton, Dickinson and Company Appoints Pamela Spikner as Senior Vice President, Chief Accounting Officer and Controller, Effective January 20, 2025

Becton, Dickinson and Company, Annual General Meeting, Jan 28, 2025

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD Announces Voluntary Recall on Intraosseous Products

Becton, Dickinson and Company Appoints Simon Campion as Executive Vice President and President of the Medical Segment, Effective July 1, 2022

Becton, Dickinson and Company (NYSE:BDX) (BD) entered into a definitive agreement to acquire Parata Systems, LLC from Frazier Healthcare Partners for $1.5 billion.

Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2022